65,437 trials
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Dose Reductions — 5; 4.8 percentage of participants
Contraception
Primary: Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation — 36; NA; NA; NA Occluded fallopian tubes
Diabetes Mellitus, Type 2
Primary: Alterations in PKC-zeta mRNA in Vastus Lateralis Skeletal Muscles — 1.76; 3.58; 2.14; 2.22 arbitrary units/ng rRNA — p=.001
Allergic Rhinitis
Primary: Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period — 3.18; 3.09; 3.87 Units on a scale (range: 0 to 12) — p=0.0066
Dementia · Alzheimer Disease
Primary: Caregiver Outcomes — 18.6; 14.5; 10.0; 10.5 units on a scale
Impetigo
Primary: Clinical Success — 55.2; 39.2 percentage of Participants — p=0.001
Allergic Rhinitis Due to Grass Pollens
Primary: Combined Score (CS) — 0.32; 0.45 Units on a scale (range: 0 to 3) — p=0.0003
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
Obesity · Insulin Resistance · Diabetes Mellitus Type 2
Primary: Serum Apelin Levels — 1.45; 1.91 ng/ml — p=0.001
Non-small Cell Lung Cancer Metastatic
Primary: Time to Disease Progression — 15 weeks
Age-related Macular Degeneration · Diabetic Macular Edema · Retinal Vein Occlusion
Primary: Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses — 0.45; 0.76; 0.11; 0.58 nM
Dental Caries
Primary: Number of New Tooth Root Caries Lesions — 1.1; 0.43; 0.56 new carious root surfaces
Dementia · Aggression · Pain
Primary: Number of Participants With Aggression as Determined by the Cohen-Mansfield Agitation Inventory (Aggression Subscale) — 8; 14; 9; 17 participants — p=0.13
Myelodysplastic Syndrome
Primary: Changes in Neutrophil Counts — -0.3 cells/mm^3
Polycystic Ovary Syndrome
Primary: Miscarriage Rate — 9; 35 participants